

*Hong Kong Exchange and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED**

**領航醫藥及生物科技有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock Code: 399)**

### **VOLUNTARY ANNOUNCEMENT**

This announcement is made by Innovative Pharmaceutical Biotech Limited (the “**Company**”) on a voluntary basis.

The board of directors of the Company (the “**Board**”) wishes to inform shareholders and potential investors of the Company that, the Company has initiated preliminary negotiation with China Travel Financial Holdings Company Limited (“**CTS**”) in relation to CTS’ potential investment in the Company (the “**Potential Investment**”) which may involve issue of convertible bonds by the Company to CTS.

CTS is a company incorporated in Hong Kong which provides financial and asset management services.

As at the date of this announcement, the Company and CTS are still at the preliminary stage of negotiation and no concrete terms have been agreed and no definitive agreement has been entered into by the Company in relation to the Potential Investment. Further announcement(s) in relation to the Potential Investment will be made by the Company as and when appropriate in compliance with the Rules Governing the Listing of Securities of the Stock Exchange of Hong Kong Limited.

**The shareholders and potential investors of the Company should note that there is no assurance that the Potential Investment and any transaction referred to in this announcement will be materialised, shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Innovative Pharmaceutical Biotech Limited**  
**Lee Nga Yan**  
*Executive Director*

Hong Kong, 17 November 2015

*As at the date of this announcement, the Board comprises Ms. Jiang Nian (chairman & non-executive director), Ms. Lee Nga Yan (executive director), Dr. Guo Yi (executive director), Mr. Tang Rong (executive director), Ms. Xiao Yan (non-executive director), Ms. Wu Yanmin (non-executive director), Ms. Chen Weijun (independent non-executive director), Dr. Zhang Zhihong (independent non-executive director) and Mr. Wang Rongliang (independent non-executive director).*